Novartis CEO Vas Narasimhan (via AP Images)
December 16, 2019 06:20 AM ESTUpdated 09:42 AM
R&D

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nals big trou­ble for a lit­tle biotech

John Carroll

Editor & Founder

No­var­tis this morn­ing re­port­ed that their asth­ma drug fe­vip­iprant flunked two more Phase III stud­ies, crush­ing their hopes in what had been a star …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

Genen­tech vet launch­es ADC start­up with $20M

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times